KLK3 and Familial prostate cancer: Further, ADT can be used as a single treatment for men with advanced prostate cancer who refuse, are incapable to take any other form of local treatment, or are asymptomatic, with a prostate-specific antigen (PSA) higher than 50 ng/mL and a tumor that is not well-differentiated (level of evidence: A) [9].